Table of Contents
| << Previous Issue | Jan 2020 (Vol: 2020, Issue: 1) | Next Issue >> |
- Section: Licensing
-
Boehringer Ingelheim Buys Rights to Enleofen’s Fibro-inflammatory Anti-IL-11 Platform
-
Roche In-licenses Amunix’s Half-life Extension Technology in US$1.5 B Deal
-
Pfizer Licenses eFFECTOR's eIF4E Inhibitors to Bolster Oncology Pipeline
-
Gilead Collaborates with Kyverna Therapeutics on T-cell Therapies
- Section: Mergers & Acquisitions
-
Lilly Pays US$1.1 B for Dermatology-Focused Dermira
-
BioNTech Acquires Struggling Neon for US$67 M
-
Astellas Continues Gene and Cell Therapy Acquisition Trend with Xyphos Buy
-
Allergan Divests Brazikumab and Zenpep to Move Forward with AbbVie Acquisition
- Section: Research & Development
-
Merck Explores KRAS Inhibitors with US$2.55 B Taisho/Astex Deal
-
Incyte Pays US$900 M Upfront to Partner with MorphoSys for Tafasitamab
-
Astellas Partners with Adaptimmune on “Off-the-shelf” Cell Therapies
-
Sanofi Adds Depth to its Pipeline with US$2.6 B Nurix Collaboration
-
Ionis Signs Discovery Deals with Empirico and Aro
RSS